# Expected Output: Visit Preparation Summary

This document shows the expected agent output when running the visit preparation prompt against the Alex Rivera reference patient pod.

---

# Visit Preparation Summary

**Patient:** Alex Rivera | **Age:** 52 | **Sex:** Male | **DOB:** August 15, 1973
**Location:** Portland, Oregon
**Primary Care Provider:** Dr. Sarah Chen
**Emergency Contact:** Maria Rivera (spouse)
**Insurance:** Blue Cross Blue Shield (PPO), active since 2020-01-01 `[Clinical]`
**Prepared:** 2026-02-20

---

## 1. Active Conditions

| Condition | ICD-10 | Onset | Status | Provenance |
|-----------|--------|-------|--------|-----------|
| Essential Hypertension | I10 | 2018-03-22 | Active | `[Clinical]` |
| Type 2 Diabetes Mellitus | E11.9 | 2020-06-10 | Active | `[Clinical]` |
| Hyperlipidemia | E78.5 | 2019-11-05 | Active | `[Clinical]` |
| Mild Persistent Asthma | J45.30 | 2005-09-01 | Active | `[Clinical]` |
| Seasonal Allergic Rhinitis | J30.2 | 2010-04-15 | Active | `[Clinical]` |

---

## 2. Current Medications

### Prescribed Medications `[Clinical]`

| Medication | Dose | Frequency | Route | Indication | Prescriber | Start Date |
|-----------|------|-----------|-------|------------|------------|-----------|
| Lisinopril | 20 mg | Once daily | Oral | Hypertension | Dr. Sarah Chen | 2024-06-15 |
| Metformin | 1000 mg | Twice daily | Oral | Type 2 Diabetes | Dr. Sarah Chen | 2020-07-01 |
| Atorvastatin | 40 mg | Once daily | Oral | Hyperlipidemia | Dr. Sarah Chen | 2019-12-01 |
| Albuterol | 90 mcg/actuation | As needed | Inhalation | Asthma | Dr. Sarah Chen | 2005-09-15 |

### Discontinued `[Clinical]`

| Medication | Dose | Reason | Discontinued |
|-----------|------|--------|-------------|
| Amlodipine | 5 mg | Switched to lisinopril monotherapy for renal protection | 2024-06-15 |

### Self-Reported Supplements and OTC Medications `[Self-Reported]`

| Item | Dose | Frequency | Reason |
|------|------|-----------|--------|
| Cetirizine (Zyrtec) | 10 mg | Once daily | Seasonal allergic rhinitis |
| Potassium Chloride | 20 mEq | Once daily | Muscle cramps |
| Fish Oil (Omega-3) | 1000 mg | Once daily | Cardiovascular health |

**FLAG:** Potassium Chloride supplement (self-reported) may interact with Lisinopril (ACE inhibitor). See Lab Results section for serum potassium level.

---

## 3. Allergies

| Allergen | Category | Reaction | Severity | Provenance |
|----------|----------|----------|----------|-----------|
| Penicillin | Medication | Hives (urticaria) | Moderate | `[Clinical]` |
| Sulfonamide antibiotics | Medication | Maculopapular rash | Mild | `[Clinical]` |
| Shellfish | Food | Throat swelling (angioedema) | **Severe** -- carries EpiPen | `[Self-Reported]` |

---

## 4. Recent Lab Results (2026-01-15)

All labs from a comprehensive metabolic panel drawn on 2026-01-15 at Cascade Regional Medical Lab. Ordered by Dr. Sarah Chen. `[Clinical]`

| Test | Result | Unit | Reference Range | Status |
|------|--------|------|----------------|--------|
| HbA1c | 7.2 | % | 4.0 - 5.6 | **Abnormal** (target <7.0%) |
| Fasting Glucose | 142 | mg/dL | 70 - 100 | **Abnormal** |
| Total Cholesterol | 198 | mg/dL | < 200 | Normal (borderline) |
| LDL Cholesterol | 112 | mg/dL | < 100 | **Abnormal** (target <100 for diabetic) |
| HDL Cholesterol | 48 | mg/dL | > 40 | Normal (low-normal) |
| Triglycerides | 190 | mg/dL | < 150 | **Abnormal** |
| Serum Creatinine | 1.1 | mg/dL | 0.7 - 1.3 | Normal |
| eGFR | 78 | mL/min/1.73m2 | > 90 | **Abnormal** (CKD Stage 2) |
| **Serum Potassium** | **5.1** | **mEq/L** | **3.5 - 5.0** | **Abnormal -- borderline high** |
| TSH | 2.1 | mIU/L | 0.4 - 4.0 | Normal |
| WBC | 6.8 | x10^3/uL | 4.5 - 11.0 | Normal |

**Key concerns:**
- Serum K+ 5.1 mEq/L above normal, relevant given lisinopril + self-reported potassium supplement
- HbA1c 7.2% above target of <7.0%, indicating suboptimal glycemic control
- LDL 112 mg/dL above target of <100 for a diabetic patient
- Triglycerides 190 mg/dL elevated
- eGFR 78 mL/min indicates mildly decreased kidney function (CKD Stage 2)

---

## 5. Vital Sign Trends (30 Days: 2026-01-20 to 2026-02-18)

### Blood Pressure -- Clinical vs Device Comparison

| Source | Systolic (Avg) | Systolic (Range) | Diastolic (Avg) | Diastolic (Range) | Provenance |
|--------|---------------|-----------------|----------------|-------------------|-----------|
| Clinical vital signs | ~132 mmHg | 120-140 mmHg | ~82 mmHg | 74-88 mmHg | `[Clinical]` |
| Omron Evolv (home) | ~129 mmHg | 120-138 mmHg | ~80 mmHg | 74-86 mmHg | `[Device]` |

**Observation:** Home blood pressure readings trend slightly lower than clinical readings, which is a common "white coat" effect. Both sources show systolic values consistently above the 120 mmHg optimal target, consistent with managed but not fully controlled hypertension.

### Heart Rate

| Source | Average | Range | Provenance |
|--------|---------|-------|-----------|
| Clinical setting | ~72 bpm | 64-80 bpm | `[Clinical]` |
| Apple Watch (resting HR) | ~68 bpm | 58-82 bpm | `[Device]` |

**Observation:** Resting heart rate from continuous wearable monitoring averages slightly lower than clinical spot-checks, which is expected. The device provides 130-168 samples/day giving high confidence in trend data. Normal range for a 52-year-old male.

---

## 6. Wellness Data Summary (30 Days) `[Device]`

### Activity (Apple Watch Series 9)

| Metric | 30-Day Average | Range | Pattern |
|--------|---------------|-------|---------|
| Steps/day | ~7,200 | 4,089 - 11,987 | Higher on weekdays, lower on weekends |
| Active energy | ~306 kcal/day | 198 - 498 kcal | Peaks on gym days |
| Exercise minutes | ~20 min/day | 0 - 45 min | ~3 sessions/week |
| Stand hours | ~9.5 hrs/day | 6 - 12 hrs | Lower on weekends |

**Observation:** Activity pattern is consistent with the reported routine (desk job, gym 3x/week). Weekend activity drops significantly (4,000-5,000 steps vs 8,000-12,000 on gym days). Several zero-exercise days noted.

### Sleep (Apple Watch Series 9)

| Metric | 30-Day Average | Range |
|--------|---------------|-------|
| Duration | ~7.1 hours/night | 5.5 - 8.5 hours |
| Quality distribution | Good: 13 nights, Fair: 9 nights, Excellent: 4 nights, Poor: 3 nights |

**Observation:** Average sleep duration is adequate (7.1 hours) but with notable variability. Three nights below 6 hours (classified "Poor") were noted on 2026-01-24, 2026-01-31, and 2026-02-07 -- all Fridays, suggesting possible end-of-week stress or social activity pattern. Poor sleep nights correlate with higher resting heart rate the following day.

---

## 7. Immunization Status `[Clinical]`

| Vaccine | Date | Status | Next Due |
|---------|------|--------|----------|
| COVID-19 mRNA (Pfizer, 2024-25 formula) | 2024-10-15 | Complete | Per updated guidance |
| Influenza (Quadrivalent, 2025-26) | 2025-09-20 | Complete | Fall 2026 |
| Tdap | 2022-03-10 | Complete | 2032 |
| PCV20 (Pneumococcal) | 2025-01-08 | Complete | One-time dose (done) |

**Status:** All immunizations are current. No action required.

---

## 8. Open Questions for the Visit

### Priority Items

1. **Potassium supplement disclosure:** The self-reported potassium chloride 20 mEq supplement does not appear in the clinical medication record. The lab note asks to "verify patient is not taking potassium supplements." This must be discussed with Dr. Chen.

2. **Serum potassium recheck:** The 2026-01-15 lab recommended rechecking potassium in 2 weeks. As of this summary date, it has been more than 4 weeks. A repeat potassium level is overdue.

3. **HbA1c management:** At 7.2%, the HbA1c is above the 7.0% target. Discuss lifestyle modifications or medication adjustment.

4. **LDL cholesterol target:** LDL at 112 mg/dL exceeds the <100 target for a patient with diabetes. Consider atorvastatin dose adjustment or additional therapy.

### Data Gaps Identified

| Gap | Detail |
|-----|--------|
| No prior lab results | Only one lab panel available (2026-01-15). Trending not possible without historical data. |
| No ophthalmology records | Diabetic patients should have annual eye exams. No records present. |
| No podiatry records | Diabetic foot exams recommended annually. No records present. |
| No dental records | Not available in the Pod |
| Supplement start context | Potassium supplement started 2025-08-01 but no documentation of leg cramp assessment |

### Discrepancies Between Sources

| Observation | Detail |
|-------------|--------|
| BP: Clinical vs Device | Clinical readings average ~3 mmHg higher systolic than home readings. Not clinically significant but consistent with white-coat effect. |
| Medication list completeness | Clinical medication list includes 5 prescribed + 3 self-reported. Supplement list includes 3 items. Cetirizine and Fish Oil appear in both. Potassium appears in both. Cross-referencing is consistent. |

---

**This summary was generated from Cascade Protocol Pod data and is intended for visit preparation purposes only. It is not a clinical document and should be reviewed with the patient's healthcare provider.**